| pubmed-article:17425621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17425621 | lifeskim:mentions | umls-concept:C0024314 | lld:lifeskim |
| pubmed-article:17425621 | lifeskim:mentions | umls-concept:C0079613 | lld:lifeskim |
| pubmed-article:17425621 | lifeskim:mentions | umls-concept:C0020964 | lld:lifeskim |
| pubmed-article:17425621 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:17425621 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17425621 | pubmed:dateCreated | 2007-4-25 | lld:pubmed |
| pubmed-article:17425621 | pubmed:abstractText | Adoptive immunotherapy using autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (auto-CTL) can regress posttransplant lymphoproliferative disorders (PTLD). Widespread applicability of auto-CTL remains constrained. Generation is time-consuming, and auto-CTL cannot be established in patients treated with the B-cell depleting antibody rituximab. By contrast, pregenerated allogeneic CTL (allo-CTL) offers immediate accessibility. Allo-CTL has previously shown efficacy in "early" polyclonal- PTLD. We treated three patients with aggressive, advanced monoclonal-PTLD following solid-organ transplantation. All were refractory to at least three prior therapies. Despite HLA disparity, there was negligible toxicity, with early in vivo antiviral efficacy and reconstitution of EBV peptide-specific immunity. Two patients attained complete remission (CR). One remains in CR 17 months following therapy, coincident with persistence of donor-derived tumor targeted EBV-specific CTL; the other died of non-PTLD related pathology. In the third patient, autopsy demonstrated homing of allo-CTL at the tumor site. Larger prospective studies of EBV-specific allo-CTL in PTLD are warranted. | lld:pubmed |
| pubmed-article:17425621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17425621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17425621 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17425621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17425621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17425621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17425621 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17425621 | pubmed:month | May | lld:pubmed |
| pubmed-article:17425621 | pubmed:issn | 1600-6135 | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:GillDD | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:CrawfordD HDH | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:WilliamsTT | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:MollerP CPC | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:WhitakerNN | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:GrimmettKK | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:GandhiM KMK | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:WilkieG MGM | lld:pubmed |
| pubmed-article:17425621 | pubmed:author | pubmed-author:DuaUU | lld:pubmed |
| pubmed-article:17425621 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17425621 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:17425621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17425621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17425621 | pubmed:pagination | 1293-9 | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:meshHeading | pubmed-meshheading:17425621... | lld:pubmed |
| pubmed-article:17425621 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17425621 | pubmed:articleTitle | Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. | lld:pubmed |
| pubmed-article:17425621 | pubmed:affiliation | Clinical Immunhaematology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia. maherG@qimr.edu.au | lld:pubmed |
| pubmed-article:17425621 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17425621 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:17425621 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17425621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17425621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17425621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17425621 | lld:pubmed |
